Obefazimod is under clinical development by Abivax and currently in Phase III for Ulcerative Colitis. According to GlobalData, Phase III drugs for Ulcerative Colitis have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Obefazimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obefazimod overview
ABX-464 is under development for the treatment of HIV infection, multiple sclerosis, Parkinson's disease, psoriasis, ulcerative colitis, non-alcoholic steatohepatitis (NASH) and pulmonary arterial hypertension. The drug candidate is first in class small molecule administered through the oral route as a capsule. The drug candidate acts by targeting Rev activity by blocking the cap-binding complex (CBC) on mRNA. It also acts by upregulating IL-22 and miR124. The drug candidate is based on Antiviral platform.
It was under development for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients, Crohn's disease and rheumatoid arthritis.
Abivax overview
Abivax operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company offers pipeline products that include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus infection. The company also develops various technology platforms including antiviral platform, immune enhancer platform and polyclonal antibody platform. Abivax is headquartered in Paris, France.
For a complete picture of Obefazimod’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
